Trill Impact Ventures and Pureos Bioventures, two venture capital funds, led a €72m funding round in MinervaX, a biotechnology company, with participation from Novo Holdings, Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. “We are delighted to announce this financing, which gives us the firepower to accelerate the development of our novel GBS vaccine. GBS can be life-threatening for newborn babies and there is no approved, universally available vaccine to date. I would like to thank the investors and the MinervaX team who have worked very hard on our vaccine candidate in preparation for the final stage of clinical development,” Per Fischer, MinervaX CEO.